Ignite Creation Date:
2025-12-25 @ 3:27 AM
Ignite Modification Date:
2025-12-26 @ 2:07 AM
Study NCT ID:
NCT03888105
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-15
First Post:
2019-03-14
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016393', 'term': 'Lymphoma, B-Cell'}, {'id': 'D008224', 'term': 'Lymphoma, Follicular'}, {'id': 'D016403', 'term': 'Lymphoma, Large B-Cell, Diffuse'}, {'id': 'D020522', 'term': 'Lymphoma, Mantle-Cell'}, {'id': 'D018442', 'term': 'Lymphoma, B-Cell, Marginal Zone'}], 'ancestors': [{'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL', 'interventionModelDescription': '5 cohorts The first 68 patients in the DLBCL cohort will be randomized; the remaining patients will not be randomized'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 515}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2019-11-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-10', 'completionDateStruct': {'date': '2028-12-15', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-10-14', 'studyFirstSubmitDate': '2019-03-14', 'studyFirstSubmitQcDate': '2019-03-20', 'lastUpdatePostDateStruct': {'date': '2025-10-15', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2019-03-25', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-07-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective Response Rate (ORR), as assessed by independent central review', 'timeFrame': 'Up to 52 weeks of study treatment', 'description': 'FL grade 1-3a/MZL'}, {'measure': 'ORR, as assessed by independent central review', 'timeFrame': 'Up to 36 weeks of study treatment', 'description': 'DLBCL/MCL/Other B-NHL'}], 'secondaryOutcomes': [{'measure': 'ORR, as assessed by the local investigator', 'timeFrame': 'Up to 52 weeks of study treatment', 'description': 'FL/MZL'}, {'measure': 'ORR, as assessed by the local investigator', 'timeFrame': 'Up to 36 weeks of study treatment', 'description': 'DLBCL/MCL/Other B-NHL'}, {'measure': 'Complete Response (CR) Rate, as assessed by the local investigator', 'timeFrame': 'Up to 52 weeks of study treatment', 'description': 'FL grade 1-3a/MZL'}, {'measure': 'CR rate, as assessed by independent central review', 'timeFrame': 'Up to 52 weeks of study treatment', 'description': 'FL grade 1-3a/MZL'}, {'measure': 'CR rate, as assessed by the local investigator', 'timeFrame': 'Up to 36 weeks of study treatment', 'description': 'DLBCL/MCL/Other B-NHL'}, {'measure': 'CR rate, as assessed by independent central review', 'timeFrame': 'Up to 36 weeks of study treatment', 'description': 'DLBCL/MCL/Other B-NHL'}, {'measure': 'Progression-Free Survival (PFS), as assessed by independent central review', 'timeFrame': 'Approximately 194 weeks following the first dose'}, {'measure': 'PFS, as assessed by the local investigator', 'timeFrame': 'Approximately 194 weeks following the first dose'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'Approximately 194 weeks following the first dose'}, {'measure': 'Duration Of Response (DOR), as assessed by independent central review', 'timeFrame': 'Approximately 194 weeks following the first dose'}, {'measure': 'DOR, as assessed by the local investigator', 'timeFrame': 'Approximately 194 weeks following the first dose'}, {'measure': 'Disease Control Rate (DCR), as assessed by independent central review', 'timeFrame': 'Up to 52 weeks of study treatment', 'description': 'FL grade 1-3a/MZL'}, {'measure': 'DCR, as assessed by the local investigator', 'timeFrame': 'Up to 52 weeks of study treatment', 'description': 'FL grade 1-3a/MZL'}, {'measure': 'DCR, as assessed by independent central review', 'timeFrame': 'Up to 36 weeks of study treatment', 'description': 'DLBCL/MCL/Other B-NHL'}, {'measure': 'DCR, as assessed by the local investigator', 'timeFrame': 'Up to 36 weeks of study treatment', 'description': 'DLBCL/MCL/Other B-NHL'}, {'measure': 'Incidence and severity of Treatment Emergent Adverse Events (TEAEs)', 'timeFrame': 'Approximately 194 weeks following the first dose'}, {'measure': 'Concentration of odronextamab', 'timeFrame': '12 weeks following end of treatment', 'description': 'End of infusion \\[EOI\\]; Concentration at a specified time t \\[Ct\\])'}, {'measure': 'Incidence of Anti-Drug Antibodies (ADA) to odronextamab over time', 'timeFrame': '12 weeks following end of treatment'}, {'measure': 'Titer of anti-drug antibodies to odronextamab over time', 'timeFrame': '12 weeks following end of treatment'}, {'measure': 'Incidence of Neutralizing antibodies (Nab) to odronextamab over time', 'timeFrame': '12 weeks following end of treatment'}, {'measure': 'Changes in scores of patient-reported outcomes as measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Cancer-30 (EORTC-QLQ-C30)', 'timeFrame': 'Approximately 194 weeks following the first dose', 'description': 'The EORTC QLQ-C30 is a self-reported, 30-item generic questionnaire developed to assess 15 domains: global health status scale, five functional scales (physical, role, emotional, cognitive, and social functioning) and nine symptom scales (fatigue, nausea, vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties).'}, {'measure': 'Changes in scores of patient-reported outcomes as measured by Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym)', 'timeFrame': 'Approximately 194 weeks following the first dose', 'description': 'Composed of the FACT-G plus the 15-item Lymphoma Subscale (LymS).'}, {'measure': 'Changes in scores of patient-reported outcomes as measured by EuroQol-5 Dimensions-3 Levels (EQ-5D-3L)', 'timeFrame': 'Approximately 194 weeks following the first dose', 'description': 'The EQ-5D-3L is a standardized instrument for use as a measure of health outcome. It is a health questionnaire that consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.'}]}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Relapsed B-NHL', 'Refractory B-NHL', 'NHL', 'Follicular lymphoma (FL)', 'Diffuse large B-cell lymphoma (DLBCL)', 'Mantle cell lymphoma (MCL)', 'Marginal zone lymphoma (MZL)', 'bispecific antibody', 'CD20'], 'conditions': ['B-cell Non-Hodgkin Lymphoma (B-NHL)']}, 'referencesModule': {'references': [{'pmid': '40902079', 'type': 'DERIVED', 'citation': 'Arnason JE, Matasar M, Luminari S, Tucker D, Sun D, Tao W, Zhu YO, Kundu K, Gupta NT, Leary A, Jankovic V, Ambati S, Mohamed H, Chaudhry A, Brouwer-Visser J. Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL. Blood Adv. 2025 Dec 9;9(23):6130-6140. doi: 10.1182/bloodadvances.2025016332.'}, {'pmid': '40472301', 'type': 'DERIVED', 'citation': 'Danilov AV, Kambhampati Thiruvengadam S, Linton K, Cumings K, Chirikov V, Mutebi A, Bains Chawla S, Chhibber A, Rivas Navarro F, Marques Goncalves F, Wang A, Ding Z, Alshreef A, Favaro E, Hoehn D, Sureda A. Indirect comparison of epcoritamab vs chemoimmunotherapy, mosunetuzumab, or odronextamab in follicular lymphoma. Blood Adv. 2025 Aug 12;9(15):3754-3765. doi: 10.1182/bloodadvances.2024015274.'}, {'pmid': '40097657', 'type': 'DERIVED', 'citation': 'Kim WS, Kim TM, Cho SG, Jarque I, Iskierka-Jazdzewska E, Poon LM, Prince HM, Zhang H, Cao J, Zhang M, Tessoulin B, Oh SY, Lim F, Carpio C, Tan TD, Ayyappan S, Gutierrez A, Cai J, Ufkin M, Shariff S, Brouwer-Visser J, Chaudhry A, Mohamed H, Ambati S, Walewski J; ELM-2 Investigators. Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial. Nat Cancer. 2025 Mar;6(3):528-539. doi: 10.1038/s43018-025-00921-6. Epub 2025 Mar 17.'}], 'seeAlsoLinks': [{'url': 'https://elmclinicalresearchstudies.com/', 'label': 'Related Info'}]}, 'descriptionModule': {'briefSummary': "This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL).\n\nThe main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab.\n\nThe study is looking at several other research questions, including:\n\n* To see if odronextamab works to destroy cancer cells\n* Side effects that may be experienced by people taking odronextamab\n* How odronextamab works in the body\n* How much odronextamab is present in the blood"}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Key Inclusion Criteria:\n\n1. For the FL grade 1-3a cohort only: Central histopathologic confirmation of the FL Grade 1 to 3a diagnosis must be obtained before study enrollment. Patients with FL grade 3b are ineligible for this cohort but may be included in the "other B-NHL" cohort. Follicular lymphoma subtyping is based on the World Health Organization (WHO) classification (Swerdlow, 2017)\n2. Disease-specific cohorts:\n\n Patients should in the judgment of the investigator require systemic therapy for lymphoma at the time of study enrollment\n * FL grade 1-3a cohort: Patients with FL grade 1-3a that has relapsed after or is refractory to at least 2 prior lines of systemic therapy, as defined in the protocol\n * DLBCL cohort: Patients with DLBCL that has relapsed after or is refractory to at least 2 prior lines of systemic therapy as defined in the protocol\n * MCL after BTK inhibitor therapy cohort: Patients with MCL who have relapsed or refractory disease to at least one prior line of systemic therapy and had prior treatment with a Bruton\'s tyrosine kinase (BTK) inhibitor\n * MZL cohort: Patients with MZL that have relapsed or is refractory to at least 2 prior lines of systemic therapy\n * Other B-NHL cohort: Patients with B-NHL other than FL grade 1-3a, DLBCL, MCL, or MZL that has relapsed after or is refractory to at least 2 prior lines of systemic therapy as defined in the protocol. New enrollment stopped for patients with Burkitt lymphoma and Burkitt-like lymphoma.\n3. Measurable disease on cross sectional imaging as defined in the protocol documented by diagnostic imaging (computed tomography (CT), or magnetic resonance imaging (MRI)\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n5. Adequate bone marrow, hepatic, and renal function as defined in the protocol\n\nKey Exclusion Criteria:\n\n1. Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS Non-Hodgkin Lymphoma (NHL) (suspected CNS lymphoma should be evaluated by lumbar puncture, as appropriate, in addition to the mandatory head CT or MRI)\n2. Treatment with any systemic anti-lymphoma therapy within 5 half-lives or within 28 days prior to first administration of study drug, whichever is shorter\n3. History of allogeneic stem cell transplantation, up to 12 months prior to first administration of study drug. The presence of acute or chronic graft-versus host disease (GVHD) will also be an exclusion\n4. Continuous systemic corticosteroid treatment with more than 10 mg per day of prednisone or anti-inflammatory equivalent within 72 hours of start of study drug\n5. History of neurodegenerative condition or CNS movement disorder. Patients with a history of seizure within 12 months prior to study enrollment are excluded\n6. Another malignancy except B-NHL in the past 5 years, with the exception of non-melanoma skin cancer that has undergone potentially curative therapy or in situ cervical carcinoma, or any other tumor that has been deemed to be effectively treated with definitive local control and with curative intent\n7. Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection; cytomegalovirus (CMV) infection as noted by detectable levels on a blood polymerase chain reaction (PCR) assay as defined in the protocol or other uncontrolled infections\n8. Known hypersensitivity to both allopurinol and rasburicase\n9. Prior treatment with an anti-CD20 x anti-CD3 bispecific therapy\n\nNote: Other protocol-defined Inclusion/Exclusion criteria apply'}, 'identificationModule': {'nctId': 'NCT03888105', 'acronym': 'ELM-2', 'briefTitle': 'A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies', 'organization': {'class': 'INDUSTRY', 'fullName': 'Regeneron Pharmaceuticals'}, 'officialTitle': 'An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma', 'orgStudyIdInfo': {'id': 'R1979-ONC-1625'}, 'secondaryIdInfos': [{'id': '2017-002139-41', 'type': 'EUDRACT_NUMBER'}, {'id': '2024-511747-25-00', 'type': 'REGISTRY', 'domain': 'CTIS number'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'FL', 'description': 'Follicular lymphoma grade 1-3a cohort', 'interventionNames': ['Drug: Odronextamab']}, {'type': 'EXPERIMENTAL', 'label': 'DLBCL', 'description': 'Diffuse large B-cell lymphoma cohort', 'interventionNames': ['Drug: Odronextamab']}, {'type': 'EXPERIMENTAL', 'label': 'MCL', 'description': 'Mantle Cell Lymphoma cohort', 'interventionNames': ['Drug: Odronextamab']}, {'type': 'EXPERIMENTAL', 'label': 'MZL', 'description': 'Marginal Zone Lymphoma cohort', 'interventionNames': ['Drug: Odronextamab']}, {'type': 'EXPERIMENTAL', 'label': 'Other B-NHL', 'description': 'Other B-cell non-Hodgkin lymphoma cohort (excluding FL Grade 1-3a, DLBCL, MCL, MZL, Waldenström macroglobulinemia \\[WM\\]); Patients with a current diagnosis of mixed histology of B-NHL with an aggressive component (such as concurrent FL and DLBCL) will be allowed', 'interventionNames': ['Drug: Odronextamab']}], 'interventions': [{'name': 'Odronextamab', 'type': 'DRUG', 'otherNames': ['REGN1979'], 'description': 'Administered by intravenous (IV) infusion', 'armGroupLabels': ['DLBCL', 'FL', 'MCL', 'MZL', 'Other B-NHL']}]}, 'contactsLocationsModule': {'locations': [{'zip': '60612', 'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'facility': 'Rush University Medical Center', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'zip': '52242', 'city': 'Iowa City', 'state': 'Iowa', 'country': 'United States', 'facility': 'University of Iowa', 'geoPoint': {'lat': 41.66113, 'lon': -91.53017}}, {'zip': '40207', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Norton Cancer Institute', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '02111', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Tufts Medical Center', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '02215', 'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Beth Israel Deaconess Medical Center', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'zip': '55905', 'city': 'Rochester', 'state': 'Minnesota', 'country': 'United States', 'facility': 'Mayo Clinic - Rochester', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}, {'zip': '07601', 'city': 'Hackensack', 'state': 'New Jersey', 'country': 'United States', 'facility': 'John Theurer Cancer Center at Hackensack UMC', 'geoPoint': {'lat': 40.88593, 'lon': -74.04347}}, {'zip': '10021', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Weill Cornell Medical College New York Presbyterian Hospital', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '11794', 'city': 'Stony Brook', 'state': 'New York', 'country': 'United States', 'facility': 'Stony Brook University Hospital', 'geoPoint': {'lat': 40.92565, 'lon': -73.14094}}, {'zip': '27257', 'city': 'Winston-Salem', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Wake Forest Baptist Medical Center', 'geoPoint': {'lat': 36.09986, 'lon': -80.24422}}, {'zip': '44195', 'city': 'Cleveland', 'state': 'Ohio', 'country': 'United States', 'facility': 'Cleveland Clinic Foundation', 'geoPoint': {'lat': 41.4995, 'lon': -81.69541}}, {'zip': '73104', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Stephenson Cancer Center', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '75390', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Harold C. Simmons Comprehensive Cancer Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '2640', 'city': 'East Albury', 'state': 'New South Wales', 'country': 'Australia', 'facility': 'Border Medical Oncology', 'geoPoint': {'lat': -36.08144, 'lon': 146.92991}}, {'zip': '2485', 'city': 'Tweed Heads', 'state': 'South Wales', 'country': 'Australia', 'facility': 'Northern NSW Local Health District The Tweed Hospital', 'geoPoint': {'lat': -28.17671, 'lon': 153.5452}}, {'zip': 'VIC 3002', 'city': 'East Melbourne', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Epworth Hospital', 'geoPoint': {'lat': -37.81667, 'lon': 144.9879}}, {'zip': '3199', 'city': 'Frankston', 'state': 'Victoria', 'country': 'Australia', 'facility': 'North Building', 'geoPoint': {'lat': -38.14458, 'lon': 145.12291}}, {'zip': '3220', 'city': 'Geelong', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Andrew Love Cancer Centre', 'geoPoint': {'lat': -38.14711, 'lon': 144.36069}}, {'zip': 'VIC 3084', 'city': 'Heidelberg', 'state': 'Victoria', 'country': 'Australia', 'facility': 'Olivia Newton John Cancer Wellness & Research Centre', 'geoPoint': {'lat': -37.75, 'lon': 145.06667}}, {'zip': '6000', 'city': 'Perth', 'state': 'Western Australia', 'country': 'Australia', 'facility': 'Royal Perth Hospital', 'geoPoint': {'lat': -31.95224, 'lon': 115.8614}}, {'zip': 'T6G172', 'city': 'Edmonton', 'state': 'Alberta', 'country': 'Canada', 'facility': 'Cross Cancer Institute', 'geoPoint': {'lat': 53.55014, 'lon': -113.46871}}, {'zip': 'B3H 2Y9', 'city': 'Halifax', 'state': 'Nova Scotia', 'country': 'Canada', 'facility': 'QEII Health Science Centre - Halifax location', 'geoPoint': {'lat': 44.64269, 'lon': -63.57688}}, {'zip': '100142', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Peking University Cancer Hospital (Beijing Cancer Hospital) (Beijing Institute for Cancer Research)', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '100730', 'city': 'Beijing', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Peking Union Medical College Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '300020', 'city': 'Tianjin', 'state': 'Beijing Municipality', 'country': 'China', 'facility': 'Institute of Hematology & Blood Diseases Hospital'}, {'zip': '400000', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'country': 'China', 'facility': 'Second Affiliated Hospital - Xinqiao Hospital', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'zip': '510000', 'city': 'Guangzhou', 'state': 'Guangdong', 'country': 'China', 'facility': 'Sun Yat-Sen University Cancer Center - Cancer Prevention and Treatment Center, Sun Yat-sen University', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '150081', 'city': 'Harbin', 'state': 'Heilongjiang', 'country': 'China', 'facility': 'The Affiliated Tumor Hospital', 'geoPoint': {'lat': 45.75, 'lon': 126.65}}, {'zip': '450000', 'city': 'Zhengzhou', 'state': 'Henan', 'country': 'China', 'facility': 'The First Affiliated Hospital of Zhengzhou University', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '430030', 'city': 'Wuhan', 'state': 'Hubei', 'country': 'China', 'facility': 'Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '215000', 'city': 'Suzhou', 'state': 'Jiangsu', 'country': 'China', 'facility': 'The First Affiliated Hospital - Soochow University', 'geoPoint': {'lat': 31.30408, 'lon': 120.59538}}, {'zip': '130021', 'city': 'Changchun', 'state': 'Jilin', 'country': 'China', 'facility': 'The First Bethune Hospital', 'geoPoint': {'lat': 43.88, 'lon': 125.32278}}, {'zip': '710061', 'city': "Xi'an", 'state': 'Shaanxi', 'country': 'China', 'facility': "The First Affiliated Hospital of Xi 'an Jiaotong University", 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}, {'zip': '200032', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'country': 'China', 'facility': 'Shanhai Cancer Center', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '610041', 'city': 'Chengdu', 'state': 'Sichuan', 'country': 'China', 'facility': 'West China Hospital', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}, {'zip': '300060', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'country': 'China', 'facility': 'Tianjin Medical University Cancer Institute', 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}, {'zip': '310003', 'city': 'Hangzhou', 'state': 'Zhejiang', 'country': 'China', 'facility': 'The First Hospital affiliated to the Medical School of Zhejiang University', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '310009', 'city': 'Hangzhou', 'state': 'Zhejiang', 'country': 'China', 'facility': 'The Second Affiliated Hospital of Zhejiang University School of Medicine', 'geoPoint': {'lat': 30.29365, 'lon': 120.16142}}, {'zip': '100191', 'city': 'Beijing', 'country': 'China', 'facility': 'Peking University - Third Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '33604', 'city': 'Pessac', 'state': 'Aquitaine', 'country': 'France', 'facility': 'Hopital Haut-Leveque', 'geoPoint': {'lat': 44.80565, 'lon': -0.6324}}, {'zip': '14000', 'city': 'Caen', 'state': 'Calvados', 'country': 'France', 'facility': 'Centre Hospitalier Universitaire de Caen - Hematologie Clinique IHBN', 'geoPoint': {'lat': 49.18585, 'lon': -0.35912}}, {'zip': '69310', 'city': 'Pierre-Bénite', 'state': 'Lyon', 'country': 'France', 'facility': 'Hopital Lyon Sud', 'geoPoint': {'lat': 45.70359, 'lon': 4.82424}}, {'zip': '59037', 'city': 'Lille', 'state': 'Nord', 'country': 'France', 'facility': 'Hopital Claude Huriez - CHR Lille', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'zip': '44093', 'city': 'Nantes', 'state': 'Pays de la Loire Region', 'country': 'France', 'facility': 'CHU Hotel Dieu Service Hematologie', 'geoPoint': {'lat': 47.21725, 'lon': -1.55336}}, {'zip': '86000', 'city': 'Poitiers', 'state': 'Vienne', 'country': 'France', 'facility': 'Chu Poitiers - Pole Regional De Cancerologie', 'geoPoint': {'lat': 46.58261, 'lon': 0.34348}}, {'zip': '75010', 'city': 'Paris', 'country': 'France', 'facility': 'Hopital Saint Louis', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '75651', 'city': 'Paris', 'country': 'France', 'facility': 'Hospital de la Pitie-Salpetriere', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'zip': '94010', 'city': 'Créteil', 'state': 'Île-de-France Region', 'country': 'France', 'facility': 'Unite Hemopathies Lymphoides Hospital Henri Mondor', 'geoPoint': {'lat': 48.79266, 'lon': 2.46569}}, {'zip': 'D-73557', 'city': 'Mutlangen', 'state': 'Gmund', 'country': 'Germany', 'facility': 'Kliniken Ostalb Stauferklinikum Schwab Gmund', 'geoPoint': {'lat': 48.82588, 'lon': 9.79714}}, {'zip': '6120', 'city': 'Halle', 'country': 'Germany', 'facility': 'University Hospital Halle Saale', 'geoPoint': {'lat': 51.48158, 'lon': 11.97947}}, {'zip': '97080', 'city': 'Würzburg', 'country': 'Germany', 'facility': 'Universitatsklinik Wurzburg, Med Klinik und Poliklinik II, Zentrum Innere Medizin', 'geoPoint': {'lat': 49.79391, 'lon': 9.95121}}, {'zip': '20122', 'city': 'Milan', 'state': 'Milan', 'country': 'Italy', 'facility': 'UOC Hematologia, Fondazione IRCCS, Ca Granda, OM Policlinico', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '40138', 'city': 'Bologna', 'country': 'Italy', 'facility': 'University of Bologna Dipartimento di Medicina Specialistica Diagnostica e Sperimentale', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'zip': '57124', 'city': 'Livorno', 'country': 'Italy', 'facility': 'Uos Ematologia - Ospedale Civile di Livorno', 'geoPoint': {'lat': 43.54427, 'lon': 10.32615}}, {'zip': '20162', 'city': 'Milan', 'country': 'Italy', 'facility': 'ASST Grande Ospedale Metropolitano Niguarda - Division of Hematology', 'geoPoint': {'lat': 42.78235, 'lon': 12.59836}}, {'zip': '28100', 'city': 'Novara', 'country': 'Italy', 'facility': 'AOU Maggiore della Carita', 'geoPoint': {'lat': 45.44694, 'lon': 8.62118}}, {'zip': '6156', 'city': 'Perugia', 'country': 'Italy', 'facility': 'Presidio Ospedaliero Santa Maria della Misericordia', 'geoPoint': {'lat': 43.1122, 'lon': 12.38878}}, {'zip': '48121', 'city': 'Ravenna', 'country': 'Italy', 'facility': 'Ospedale Santa Maria delle Croci', 'geoPoint': {'lat': 44.41344, 'lon': 12.20121}}, {'zip': '42123', 'city': 'Reggio Emilia', 'country': 'Italy', 'facility': 'Arcispedale Santa Maria Nuova', 'geoPoint': {'lat': 44.69825, 'lon': 10.63125}}, {'zip': '21100', 'city': 'Varese', 'country': 'Italy', 'facility': "Ospedale dell'Angelo - Varese", 'geoPoint': {'lat': 45.82058, 'lon': 8.82511}}, {'zip': '30174', 'city': 'Venice', 'country': 'Italy', 'facility': 'Ospedale DellAngelo Di Mestre', 'geoPoint': {'lat': 45.43713, 'lon': 12.33265}}, {'zip': '466-8650', 'city': 'Nagoya', 'state': 'Aichi-ken', 'country': 'Japan', 'facility': 'Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'zip': '460-0001', 'city': 'Nagoya', 'state': 'Aiti', 'country': 'Japan', 'facility': 'National Hospital Organization Nagoya Medical Center', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'zip': '260-8717', 'city': 'Chiba', 'state': 'Chiba', 'country': 'Japan', 'facility': 'Chiba Cancer Center', 'geoPoint': {'lat': 35.6, 'lon': 140.11667}}, {'zip': '277-8577', 'city': 'Kashiwa-shi', 'state': 'Chiba', 'country': 'Japan', 'facility': 'National Cancer Center Hospital East'}, {'zip': '791-0280', 'city': 'Matsuyama', 'state': 'Ehime', 'country': 'Japan', 'facility': 'National Hospital Organization Shikoku Cancer Center', 'geoPoint': {'lat': 33.83916, 'lon': 132.76574}}, {'zip': '811-1395', 'city': 'Fukuoka', 'state': 'Hukuoka', 'country': 'Japan', 'facility': 'National Hospital Organization National Kyushu Cancer Center', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'zip': '650-0047', 'city': 'Kobe', 'state': 'Hyōgo', 'country': 'Japan', 'facility': 'Kobe City Medical Center General Hospital', 'geoPoint': {'lat': 34.6913, 'lon': 135.183}}, {'zip': '259-1193', 'city': 'Isehara-Shi', 'state': 'Kanagawa', 'country': 'Japan', 'facility': 'Tokai University Hospital'}, {'zip': '602-8566', 'city': 'Kyoto', 'state': 'Kyoto', 'country': 'Japan', 'facility': 'University Hospital Kyoto Prefectural University of Medicine', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'zip': '545-8586', 'city': 'Osaka', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Osaka Metropolitan University Hospital', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'zip': '350-1298', 'city': 'Hidaka', 'state': 'Saitama', 'country': 'Japan', 'facility': 'Saitama Medical University International Medical Center', 'geoPoint': {'lat': 35.91664, 'lon': 139.36233}}, {'zip': '104-0045', 'city': 'Chuo Ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'National Cancer Center Hospital - Tsukiji Campus'}, {'zip': '990-9585', 'city': 'Yamagata', 'state': 'Yamagata', 'country': 'Japan', 'facility': 'Yamagata University Hospital', 'geoPoint': {'lat': 38.23333, 'lon': 140.36667}}, {'zip': '852-8511', 'city': 'Nagasaki', 'country': 'Japan', 'facility': 'Japanese Red Cross Nagasaki Genbaku Hospital', 'geoPoint': {'lat': 32.75, 'lon': 129.88333}}, {'zip': '02-781', 'city': 'Warsaw', 'state': 'Masovian Voivodeship', 'country': 'Poland', 'facility': 'Centrum Onkologii Instytut im M Sklodowskiej CurieOddzial Chorob United Kingdomladu Chlonnego', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '80-214', 'city': 'Gdansk', 'state': 'Pomeranian Voivodeship', 'country': 'Poland', 'facility': 'Uniwersyteckie Centrum', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'zip': '81519', 'city': 'Gdynia', 'state': 'Pomeranian Voivodeship', 'country': 'Poland', 'facility': 'Pomorskie Hospitals SP. Z O. O. Oncology And Radiotherapy Ward', 'geoPoint': {'lat': 54.51889, 'lon': 18.53188}}, {'zip': '80-214', 'city': 'Gdansk', 'country': 'Poland', 'facility': 'Uniwersyteckie Centrum Kliniczne', 'geoPoint': {'lat': 54.35227, 'lon': 18.64912}}, {'zip': '81-519', 'city': 'Gdynia', 'country': 'Poland', 'facility': 'Szpitale Pomorskie spSp. Z.o.o.', 'geoPoint': {'lat': 54.51889, 'lon': 18.53188}}, {'zip': '93-513', 'city': 'Lodz', 'country': 'Poland', 'facility': 'Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. Mikolaja Kopernika w Lodzi (Copernicus Memorial Hospital)', 'geoPoint': {'lat': 51.77058, 'lon': 19.47395}}, {'zip': '02-776', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Instytut Hematologii I Transfuzjologii Klinika Hematologii', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '50-367', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'Uniwersytecki Szpital Kliniczny we Wroclawiu, Klinika Hematologii, Terapii Komorkowych i Chorob Wewnetrznych', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '119074', 'city': 'Singapore', 'country': 'Singapore', 'facility': 'National University Hospital', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'zip': '169608', 'city': 'Singapore', 'country': 'Singapore', 'facility': 'Singapore General Hospital', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'zip': '217562', 'city': 'Singapore', 'country': 'Singapore', 'facility': 'Icon Soc Farrer Park', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}, {'zip': '682-714', 'city': 'Ulsan', 'state': 'Daegu', 'country': 'South Korea', 'facility': 'University of Ulsan College of Medicine'}, {'zip': '10408', 'city': 'Gyeonggi-do', 'state': 'Gyeonggi-do', 'country': 'South Korea', 'facility': 'National Cancer Center', 'geoPoint': {'lat': 37.58944, 'lon': 126.76917}}, {'zip': '49201', 'city': 'Busan', 'country': 'South Korea', 'facility': 'Dong-A University Hospital', 'geoPoint': {'lat': 35.10168, 'lon': 129.03004}}, {'zip': '3080', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Seoul National University Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '3722', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Severance Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '6351', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Samsung Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '6591', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'The Catholic University of Korea Seoul St Marys Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '7985', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Ewha Womans University Mokdong Hospital - Hemato Oncology', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '07120', 'city': 'Palma', 'state': 'Balearic Islands', 'country': 'Spain', 'facility': 'Hospital Universitari Son Espases', 'geoPoint': {'lat': 39.56939, 'lon': 2.65024}}, {'zip': '07198', 'city': 'Palma', 'state': 'Balearic Islands', 'country': 'Spain', 'facility': 'Hospital Son Llatzer', 'geoPoint': {'lat': 39.56939, 'lon': 2.65024}}, {'zip': '8907', 'city': 'Barcelona', 'state': 'Catalonia', 'country': 'Spain', 'facility': 'Ico Lhospitalet - Hospital Duran i Reynals', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28223', 'city': 'Pozuelo de Alarcón', 'state': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario Quiron Salud Madrid', 'geoPoint': {'lat': 40.43293, 'lon': -3.81338}}, {'zip': '08035', 'city': 'Barcelona', 'country': 'Spain', 'facility': "Hospital Universitario Vall d'Hebron", 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '8036', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital Clinic de Barcelona - Planta 4 Escalera', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '8041', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hospital de la Santa Creu i Sant Pau', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '28040', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario Fundacion Jimenez Diaz', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28041', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario 12 de Octubre', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '28050', 'city': 'Madrid', 'country': 'Spain', 'facility': 'Hospital Universitario HM Sanchinarro', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'zip': '37007', 'city': 'Salamanca', 'country': 'Spain', 'facility': 'Hospital Universitario de Salamanca', 'geoPoint': {'lat': 40.96882, 'lon': -5.66388}}, {'zip': '46026', 'city': 'Valencia', 'country': 'Spain', 'facility': 'Hospital Universitari i Politecnic La Fe', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'zip': '83301', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Chang Gung Memorial Hospital Kaohsiung', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '40447', 'city': 'Taichung', 'country': 'Taiwan', 'facility': 'China Medical University', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '704', 'city': 'Tainan', 'country': 'Taiwan', 'facility': 'National Cheng Kung University', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '736', 'city': 'Tainan', 'country': 'Taiwan', 'facility': 'Chi-Mei Medical Center - Liuying', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '10002', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'National Taiwan University Hospital', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '11251', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Koo Foundation Sun Yat-Sen Cancer Center', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '11490', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Tri-Service General Hospital', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '333', 'city': 'Taoyuan District', 'country': 'Taiwan', 'facility': 'Chang Gung Medical Foundation-', 'geoPoint': {'lat': 24.9896, 'lon': 121.3187}}, {'zip': 'TR1 3LJ', 'city': 'Truro', 'state': 'Cornwall', 'country': 'United Kingdom', 'facility': 'Royal Cornwall Hospital', 'geoPoint': {'lat': 50.26526, 'lon': -5.05436}}, {'zip': 'PL6 8DH', 'city': 'Plymouth', 'state': 'Devon', 'country': 'United Kingdom', 'facility': 'Derriford Hospital and the Royal Eye Infirmary', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'zip': 'SM2 5PT', 'city': 'Sutton', 'state': 'Surrey', 'country': 'United Kingdom', 'facility': 'The Royal Marsden Hospital', 'geoPoint': {'lat': 51.35, 'lon': -0.2}}, {'zip': 'CF14 4XW', 'city': 'Cardiff', 'state': 'Wales', 'country': 'United Kingdom', 'facility': 'University Hospital of Wales', 'geoPoint': {'lat': 51.48, 'lon': -3.18}}, {'zip': 'SE5 9RS', 'city': 'London', 'country': 'United Kingdom', 'facility': 'Kings College Hospital', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'overallOfficials': [{'name': 'Clinical Trial Management', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Regeneron Pharmaceuticals'}]}, 'ipdSharingStatementModule': {'url': 'https://vivli.org/', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR', 'ANALYTIC_CODE'], 'timeFrame': 'When Regeneron has:\n\n* received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development\n* made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)\n* the legal authority to share the data, and\n* ensured the ability to protect participant privacy', 'ipdSharing': 'YES', 'description': 'All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing', 'accessCriteria': "Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf"}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Regeneron Pharmaceuticals', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}